Wednesday, March 27, 2013
Thursday, March 21, 2013
Thursday, March 14, 2013
Wednesday, March 13, 2013
ISIS-CRP Phase I Results: The Decreasing Competitiveness of RNaseH Antisense for Liver Gene Knockdown
Thursday, March 7, 2013
As the recent high-profile pulling from the market of a pegylated peptide (Omontys by Affymax) due to hypersensitivity, even anaphylactic reactions demonstrate (and also the infusion reactions reported by Alnylam in their SNALP RNAi Therapeutics trials), administration-related hypersensitivity reactions are an issue for the entire drug development arena. In order to rescue the value of a number of blockbuster franchises, I expect that changing administration schedules could be one area attracting increased attention. A patent here could have unexpected value.
The efforts above are a reminder that cancer could be an even bigger commercial opportunity for RNAi Therapeutics than liver-related indications. The genome-wide targeting opportunity with RNAi Therapeutics has not been lost. The pharmaceutical industry is watching.
Register for the GTC RNAi Research and Therapeutics meeting in San Francisco today (June 20-21). Get a free RNAi Therapeutics blog T-shirt and 20% discount on registration by entering discount code 'RNABLG13'.
Friday, March 1, 2013
Disclaimer: This blog is not intended for distribution to or use by any person or entity who is a citizen or resident of, or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject the author or any of his collaborators and contributors to any registration or licensing requirement within such jurisdiction. This blog expresses only my opinions, they may be flawed and are for entertainment purposes only. Opinions expressed are a direct result of information which may or may not be accurate, and I do not assume any responsibility for material errors or to provide updates should circumstances change. Opinions expressed in this blog may have been disseminated before to others. This blog should not be taken as investment, legal or tax advice. The investments referred to herein may not be suitable for you. Investments particularly in the field of RNAi Therapeutics and biotechnology carry a high risk of total loss. You, the reader must make your own investment decisions in consultation with your professional advisors in light of your specific circumstances. I reserve the right to buy, sell, or short any security including those that may or may not be discussed on my blog.